Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 5;6(5):e005568.
doi: 10.1161/JAHA.117.005568.

Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment

Eric E Smith  1 , Alicja Cieslak  2 , Philip Barber  2 , Jerry Chen  3 , Yu-Wei Chen  4   5 , Ida Donnini  6 , Jodi D Edwards  7 , Richard Frayne  2 , Thalia S Field  8 , Janka Hegedus  2 , Victoria Hanganu  2 , Zahinoor Ismail  2 , Jamila Kanji  2 , Makoto Nakajima  9 , Raza Noor  7 , Stefano Peca  2 , Demetrios Sahlas  3 , Mukul Sharma  3 , Luciano A Sposato  10 , Richard H Swartz  7 , Charlotte Zerna  2 , Sandra E Black  7 , Vladimir Hachinski  10
Affiliations

Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment

Eric E Smith et al. J Am Heart Assoc. .
No abstract available

Keywords: cerebrovascular disease; clinical trials; cognitive impairment; stroke; systematic review; vascular dementia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial design considerations categorized by population (A), intervention (B), and outcome (C). AD indicates Alzheimer disease; CADASIL, cerebral autosomal dominant arteriopathy with subcortical ischemic leukoencephalopathy; MCI, mild cognitive impairment; VCI, vascular cognitive impairment .
Figure 2
Figure 2
Flow chart showing study selection. ALOIS indicates the Cochrane Dementia and Cognitive Improvement Group's Specialized Register; VCI, vascular cognitive impairment.
Figure 3
Figure 3
Published randomized controlled trials of pharmacological and nonpharmacological treatments for VCI. Data were abstracted from 130 eligible trials. The area of the bubble is linearly proportional to the total randomized sample size. Bubbles are color coded according to the presumed mechanism of action. “Multiple” indicates that the trial compared drugs or strategies with more than 1 mechanism, with or without an additional untreated control group. Nonpharmacological strategies included group therapy, acupuncture, and transcranial magnetic stimulation or direct current stimulation. NMDA, N‐methyl‐d‐aspartate.
Figure 4
Figure 4
Drug development status of medications for patients with vascular cognitive impairment. Phase III was operationally defined retrospectively as randomized controlled trials with ≥300 participants, later phase II as ≥100 to 299 participants, and early phase II as <100 participants. Data from trials with untreated controls (mostly receiving a placebo) were used to generate the figure. A single large trial (>300 participants) of the calcium channel blockers nicardipine vs clentiazem was not included because there was no untreated control arm.
See this image and copyright information in PMC

References

    1. Dementia: a public health priority. World Health Organization 2012. Available at http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed April 20, 2017.
    1. O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386:1698–1706. - PubMed
    1. Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, Brayne C; Medical Research Council Cognitive F, Ageing C . A two‐decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382:1405–1412. - PMC - PubMed
    1. Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374:523–532. - PMC - PubMed
    1. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672–2713. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources